CD8.sup.+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

CD8.sup.+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

A study of hospitalized patients infected with SARS-CoV-2 and who have liquid or solid cancer suggests that hematologic malignancy is an independent risk factor for mortality and that CD8.sup.+ T cells might limit infection in this setting irrespective of humoral immunity.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature medicine 2021-07, Vol.27 (7), p.1280
Hauptverfasser: Bange, Erin M, Han, Nicholas A, Wileyto, Paul, Kim, Justin Y, Gouma, Sigrid, Robinson, James, Greenplate, Allison R, Hwee, Madeline A, Porterfield, Florence, Owoyemi, Olutusin, Naik, Karan, Zheng, Cathy, Galantino, Michael, Weisman, Ariel R, Ittner, Caroline A.G, Kugler, Emily M, Baxter, Amy E
Format: Artikel
Sprache:eng
Schlagworte:
Cancer patients
CD8 lymphocytes
Health aspects
Hospital patients
Immune response
Leukemia
Lymphomas
Patient outcomes
Statistics
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A study of hospitalized patients infected with SARS-CoV-2 and who have liquid or solid cancer suggests that hematologic malignancy is an independent risk factor for mortality and that CD8.sup.+ T cells might limit infection in this setting irrespective of humoral immunity.
ISSN:1078-8956
1546-170X
DOI:10.1038/s41591-021-01386-7